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ABSTRACT
Background: The effect of salt on cerebral small vessel disease (SVD) is poorly 
understood. We assessed the effect of dietary salt on the cerebral tissue of the stroke-
prone spontaneously hypertensive rat (SHRSP) - a relevant model of sporadic SVD -
at both the gene and protein level. Methods: Brains from 21 week old SHRSP and 
Wistar-Kyoto rats, half additionally salt-loaded (via a 3 week regime of 1% NaCl in 
drinking water) were split into 2 hemispheres and sectioned coronally – one 
hemisphere for mRNA microarray and qRT-PCR, the other for 
immunohistochemistry using a panel of antibodies targeting components of the 
neurovascular unit. Results: We observed differences in gene and protein expression 
affecting the acute phase pathway and oxidative stress (ALB, AMBP, APOH, AHSG 
and LOC100129193, up-regulated in salt-loaded WKY versus WKY, >2-fold), active 
microglia (increased Iba-1 protein expression in salt-loaded SHRSP versus salt-
loaded WKY, p<0.05), vascular structure (ACTB & CTNNB, up-regulated in salt-
loaded SHRSP versus SHRSP, >3-fold; CLDN-11,VEGF and VGF downregulated >-
2-fold in salt-loaded SHRSP versus SHRSP) and myelin integrity (MBP down-
regulated in salt loaded WKY rats versus WKY, >2.5-fold). Changes of salt-loading 
were more pronounced in SHRSP and occurred without an increase in blood pressure
in WKY rats. Conclusion: Salt exposure induced changes in gene and protein 
expression in an experimental model of SVD and its parent rat strain in multiple 
pathways involving components of the glio-vascular unit. Further studies in pertinent 
experimental models at different ages would help clarify the short and long-term 
effect of dietary salt in SVD. 
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ABBREVIATIONS
SHRSP – Spontaneously Hypertensive Stroke-Prone Rat
WKY – Wistar Kyoto Rat
SVD – Small Vessel Disease
CVD – Cerebrovascular Disease
BP – Blood Pressure
WMH – White Matter Hyperintensities
RP – Rank Products
FDR – False Discovery rate
CT – Cycle Threshold
qRT-PCR – Quantitative Real Time Polymerase Chain Reaction
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INTRODUCTION
The association between high dietary salt intake and stroke incidence and mortality is 
well known(1, 2). However, the true interaction between salt intake, blood pressure 
and cerebrovascular disease (CVD) remains incompletely understood. Literature has 
begun to highlight a possible mechanism of salt independent of, or only partially 
mediated by, hypertension(1). For example epidemiology evidence suggests salt 
intake is associated with increased stroke risk and CVD independent of blood 
pressure (BP)(3), however this study, like many others, was conducted in a general 
(heterogeneous) stroke population and the effect of salt may differ across stroke 
subtypes. Recently, a study of minor ischaemic patients found an association
between increased dietary salt intake and greater volume of white matter 
hyperintensities (WMH), the most frequent feature of small vessel disease (SVD), 
independent of BP or history of hypertension(4). Long term high dietary salt intake 
has also been positively associated with worse SVD features on neuroimaging, 
including lacunes, microbleeds, severe WMH’s and worse total SVD scores in 
patients with lacunar versus cortical stroke(5).
A major drawback of clinical studies is the inability to assess accurately patients’ salt 
intake. Experimental models provide an opportunity to do this in a controlled 
environment. Indeed a recent study has demonstrated that excess dietary salt 
suppresses resting cerebral blood flow and endothelial function, leading to cognitive 
impairment in mice– mechanisms and end stage outcomes relevant to SVD(6).
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The Spontaneously Hypertensive Stroke-Prone Rat (SHRSP)is considered to be a 
relevant model of sporadic SVD (7, 8) but most studies investigating salt use in this 
strain have focused on kidney disorders or malignant hypertension with sparse 
investigation of cerebral tissue, particularly in relation to SVD. 
We aimed to characterise genetic and protein changes in cerebral tissue of SHRSP 
rats compared with the parent WKY rats, with and without added dietary salt, to 
determine the impact of salt on the glio-vascular unit changes that are characteristic 
of SVD. 
METHODS
For full methods see supplementary information. 
Animals
All animals were kept and experiments conducted according to UK regulations for 
live animal research in licensed laboratories (licence No. 60/3618) and the ARRIVE 
(Animal Research: Reporting In Vivo Experiments) guidelines 
(http://www.nc3rs.org/ARRIVE). All animals were obtained from the Glasgow 
colony and kept in identical conditions(9).
Study animals consisted of male rats aged 21 weeks reared on either a normal diet 
(n = 5 per strain) or a normal diet until age 18 weeks plus ‘salt-loading’ via 1% NaCl 
added to drinking water from 18 to 21 weeks (n = 5 per strain). 
Tail cuff plethysmography was used to take weekly measurements of systolic BP. 
Animals were sacrificed by overdose of isofluorane plus exsanguination. Brains were 
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extracted and divided into left and right hemispheres – one fixed in formalin for 
immunohistochemistry, one snap frozen in liquid nitrogen for RNA extraction.
Microarray& qRT-PCR
)RUP51$DQDO\VLVRQHKHPLVSKHUHZDVVQDSIUR]HQDQGௗPPFRURQDOVOLFHVIURP
a frontal and a mid-coronal region were cut using a Zivic® rat slicer matrix – these 
areas are typically the most damaged areas in SHRSP(9). RNA was extracted using a 
Qiagen RNAeasy lipid tissue minikit (Qiagen Ltd., Manchester, UK) and transcribed 
to cRNA using an Ambion® Illumina® Total Prep RNA amplification kit (Applied 
Biosystems, Foster City, CA, USA). The resulting cRNA was loaded onto a 
RatRef12 microarray chip (Illumina, San Diego, CA, USA). Chips were scanned on 
an Illumina® Bead Reader (Illumina, San Diego, CA, USA) for fluorescence 
intensity. Samples were randomized throughout and were hybridized to chips and 
scanned at the same time. The same DNase-treated RNA was used as a template for 
synthesis of cDNA, qRT-PCR reactions using Applied Biosystems Taqman® Gene 
Expression Assay (Applied Biosystems, Foster City, CA, USA). The reaction mix 
included Taqman® universal master mix (Applied Biosystems, Foster City, CA, 
USA) plus GAPDH (VIC® labelled)] and Taqman® probes corresponding to genes
of interest (FAM® labelled).  Results are reported according to the Minimum 
Information About a Microarray Experiment (MIAME) 2.0 criteria 
(http://www.mged.org/Workgroups/MIAME/miame_2.0.html). 
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Immunohistochemistry
Formalin-fixed paraffin-embedded 3mm frontal and mid coronal sections were cut 
into 7-m sections. Antibodies assessed various components of the neurovascular 
unit (for full details of antibodies used see (9)), claudin-5, collagen IV, smooth 
muscle actin (SMA), collagen I, glial fibrillary acidic protein (GFAP), matrix 
metalloproteinase 9 (MMP9), ionized calcium-binding adaptor molecule 1 (Iba-1) 
and Myelin Basic Protein (MBP). Antigen heat retrieval was performed before slides 
were blocked in hydrogen peroxide followed by either rabbit or swine seUXPƍ-
diaminobenzidine tetrahydrochloride with a haematoxylin counterstain revealed 
immunoreactivity. Tris-buffered saline replaced the primary antibody in negative 
controls.
Data analysis
Microarray data were analysed using Rank Products (RP) analysis complete with 
Bejamini-+RFKEHUJIDOVHGLVFRYHU\UDWH)'5DGMXVWPHQW)'5ௗZDV
considered significant. A minimum individual fold change for significance was not 
set due to an interest in pathway interactions. Ingenuity Pathway Analysis® (IPA) 
(Ingenuity Systems, http://www.ingenuity.com) analysed data using both a 
prespecified candidate gene approach and a genome-wide approach Significance of 
pathways was assessed using one-sided Fisher's exact tests. 
qRT-PCR data (cycle threshold (CT) values) were analysed in Microsoft® Excel by 
comparing mean delta cycle threshold (dCT) values vs. the housekeeper gene using a 
Student's t-test. 
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Percentage staining of immunohistochemistry was measured using ImagePro™ 
software (version 6.2; Media Cybernetics, Bethesda, MD, USA), blinded to species 
and age, in defined areas of cortical, deep grey and white matter. Statistical analysis 
was performed in Minitab using a general linear model (two-way ANOVA) followed 
by Tukeys test for pairwise comparisons. P values of p<0.05 were considered 
statistically significant. All data are shown as mean ± SEM.
RESULTS
Weekly systolic BP readings from 16 to 21 weeks were significantly higher in salt-
loaded than in non-salt loaded SHRSP (average 237±4.mmHg versus 200±7mmHg, 
p=<0.05). No difference in systolic BP was found between age-matched salt-loaded 
WKY versus WKY even at 21 weeks (154±3mmHg vs 152±4 mmHg).
Genetic data
Salt-loaded versus age-matched non-salt loaded animals - genome wide approach: 
Both strains: In the frontal brain section, 59 genes were differentially expressed in 
salt-loaded WKY versus WKY (figure 1) Within these, a small network of 11, 
centred on amyloid precursor protein (APP), showed down-regulation in salt-loaded 
WKY (figure 2a). When salt-loaded SHRSP versus SHRSP data were overlaid, all of 
the genes surrounding APP (except albumin (ALB) and APP itself) were significantly 
up-regulated in the salt-loaded SHRSP suggesting a different response to salt-loading 
(figure 2b). Within the frontal section, we also found a small network of genes 
centred round beta actin (ACTB) which were almost all up-regulated in salt-loaded 
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SHRSP versus SHRSP (figure 3), including some that are functionally related to 
maintaining the structural integrity of the vascular cytoskeleton (e.g. ACTB, Destrin 
(DSTN) and beta-catenin (CTNNB1)).
The top 10 up and down-regulated genes (table 1): 
Salt-loaded, WKY: The most up-regulated gene in both brain sections was 
LOC100129193 (major urinary protein pseudogene), +16-fold in the frontal section 
and +4-fold in the mid-coronal section. The only gene to appear in the 10 most highly 
up-regulated genes of both brain sections was ALB (+2-fold in both sections). In fact, 
a cluster of genes closely associated with ALB and the acute phase response pathway 
were up-regulated in the frontal section by at least 2-fold: Alpha-1-
microglobulin/bikunin precursor (AMBP), Apolipoprotein H (APOH) and Alpha-2-
HS-glycoprotein (AHSG). Transthyretin (TTR) – a transport protein implicated in 
amyloidosis - was also upregulated in the mid-coronal section by 2-fold. The most 
down-regulated gene in salt-loaded versus non-salt loaded WKY was MBP in the 
frontal section (-2.6-fold). Only three other genes were highly down-regulated in both 
sections: ACTB down -2.3-fold and N-ethylmaleimide-sensitive factor (NSF) and M2-
pyruvate kinase (PKM2) both down -2-fold. 
Salt-loaded, SHRSP: Here, there was much less consistency between brain sections. 
Like salt-loaded versus non-salt loaded WKY, TTR was upregulated in the frontal 
section but this time by +53.4-fold. In contrast to the salt-loading WKY comparison 
above, ACTB was upregulated in the frontal section (+3.7-fold). In the mid-coronal 
section LOC100129193 was the most up-regulated (+3.3-fold) similar to salt-loaded 
versus non-salt loaded WKY. Here there were also two solute carriers SLC17a6 (+2.2-
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fold) and SLC24a2 (+2.0-fold) as well as ALB (+1.7-fold) which were upregulated. In 
the frontal section, no gene was substantially down-regulated, but several were 
downregulated by approximately a -2-fold, topped by VOPP1 (vesicular, 
overexpressed in cancer, prosurvival protein 1) with a fold change of -2.7. The 
remaining genes all had fold changes less than 2 and the only other gene of note was 
CYR61, an angiogenic inducer (down-regulated -1.9-fold). In the mid-coronal section, 
only 8 genes were significantly down-regulated with salt-loading in the SHRSP, of 
which TTR came top with a fold change of -3.1, which directly contrasts the up-
regulation seen in the frontal section of salt-loaded SHRSP v SHRSP and the mid-
coronal section of salt-loaded WKY versus WKY. This was followed by Von 
Willebrand factor (VWF; -2.3-fold) and vascular growth factor (VGF; -1.9-fold). 
Salt-loaded SHRSP versus WKY: Between the two salt-loaded strains the most 
differentially expressed genes were representative of those previously found at ages 5 
and 16 weeks in non-salt loaded WKY and SHRSP(10). GUCY1a3 (Guanylate cyclase 
soluble subunit alpha-3), RSP9 (Repeat sequence probe 9) and RGD1564649 (similar 
to 40S ribosomal protein S9) were up-regulated in SHRSP by at least +14-fold in both 
brain sections, whilst MRPL18 (mitochondrial ribosomal protein L18), HCG2004593
(ribosomal protein L17 pseudogene 39) and LOC100125697 (low-molecular-weight 
glutenin storage protein) were down-regulated by a minimum of -5-fold in both brain 
sections. ALB was also down-regulated in both brain sections by at least -3.5-fold.
Analysis of over-represented biological pathways and genes within biological 
pathways of interest on Ingenuity Pathway Analysis (figure 4): 
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Tight junctions (blood brain barrier) (9, 11, 12) and the acute phase response (a rapid 
inflammatory response that provides protection against microorganisms using non-
specific defence mechanisms)(13) are considered to be affected in cerebral SVD, so 
we looked for genes of interest which were differentially expressed within these 
pathways. 
The acute phase response signalling pathway contained the most differentially 
expressed genes in both rat strains for all salt versus no salt comparisons, consistently 
appearing within the top five affected pathways. Salt-loading in both rat strains was 
associated with changes within the tight junction signalling pathway of frontal brain 
sections. Pathways pertaining to oxidative stress and leukocyte extravasation also 
contained a high proportion of differentially expressed genes in both strains with salt-
loading versus non-salt loading particularly in the frontal brain sections. 
In the frontal section of salt-loaded versus not-salt loaded SHRSP, we found Claudin-
11 (CLDN11) to be down-regulated -2.3-fold within the tight junction signalling 
pathway. However, we also found CLDN11 to be up-regulated in salt-loaded SHRSP 
when compared to salt-loaded WKY (+1.8-fold change) suggesting a difference in 
response to salt between the strains.  
In the acute phase response pathway, ALB was consistently up-regulated across all salt 
comparisons in both strains. Additionally, in WKY in the frontal section, a group of 
closely associated genes, AMBP AHSG and APOH were up-regulated by 
approximately 2-fold with salt-loading. 
qRT-PCR of candidate genes: 
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From the microarray results above, we chose the following genes for quantitative 
validation with qRT-PCR: MBP, ACTB and SLC24a2. MBP was chosen due to down-
regulation (>-2-fold) in the frontal section of salt-loaded WKY versus non-salt loaded 
WKY and any subsequent effect on protein expression could be directly assessed via 
immunohistochemistry. ACTB was chosen due to significant down-regulation in salt-
loaded WKY versus non-salt loaded WKY in both brain sections (>-2-fold) whilst also 
showing a significant up-regulation in the frontal section of SHRSP+NaCl versus 
SHRSP (+3.7-fold). SLC24a2 was chosen because, like ACTB, the microarray data 
showed two significant results. Firstly SLC24a2 was significantly down-regulated in 
both sections of salt-loaded WKY versus non-salt loaded WKY (-2-fold). Secondly 
we found SLC24a2 to be significantly up-regulated in the mid-coronal section of salt-
loaded SHRSP (+2-fold) versus non-salt loaded SHRSP. Unfortunately qRT-PCR did 
not replicate any of the significant differences in the 3 genes of interest. 
Immunohistochemistry data.
For full numerical immunohistochemical data see supplementary material – tables S1-
S4.
Salt-loading, WKY: In WKY, salt-loading was associated with reduced GFAP 
immunoreactivity in the frontal section cortical grey matter (p<0.05) (figure 5). 
Claudin-5 immunoreactivity was reduced in all areas particularly in the frontal cortex, 
although this did not reach statistical significance. MBP immunoreactivity (figure 6) 
was significantly increased in the cortical grey matter of the frontal section (p=0.01), 
13 
 
whilst significantly decreased in the white matter of the same section (p<0.05). MBP 
in the white matter of the mid-coronal section was significantly increased (p<0.05). 
Salt-loading, SHRSP: In SHRSP, salt-loading was associated with decreased Collagen 
IV in the cortical grey matter of the frontal section (p<0.05). Iba-1 expression varied 
greatly within the cortical grey matter of the two brain sections - it was significantly 
lower in the cortical grey matter of the frontal section (p<0.01), but significantly higher 
in cortical grey matter of the mid-coronal section (p=0.01). GFAP immunoreactivity 
was significantly increased in the white matter of the mid-coronal section (p<0.01) in 
salt-loaded SHRSP versus non-salt loaded SHRSP (figure 5). Salt-loaded SHRSP 
tended to have less SMA immunoreactivity across all regions in both frontal and mid-
coronal sections although this did not reach statistical significance. MBP 
immunoreactivity was significantly decreased in salt-loaded SHRSP in the white 
matter of the mid-coronal section (p<0.01) (figure 6).
Salt-loading, WKY versus SHRSP: Salt-loading obscured some between-strain 
differences seen in rats fed normal chow (9), and exaggerated others. For example, we 
did not see the difference in Claudin-5 immunoreactivity previously found between 
WKY and SHRSP rats fed a normal diet repeated in the salt-loaded animals, as the 
amount of Claudin-5 immunoreactivity in salt-loaded WKY rats had also decreased. 
GFAP immunoreactivity was significantly increased in the cortical and deep grey 
matter of the frontal section (both p<0.05) and the white matter of the mid-coronal 
section (p<0.01) of salt-loaded SHRSP versus salt-loaded WKY (figure 5). Iba-1
immunoreactivity was no different between salt-loaded strains in the frontal brain 
section, however, in the mid-coronal section salt-loaded SHRSP had significantly 
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increased Iba-1 immunoreactivity in the cortical grey and deep matter compared with 
salt-loaded WKY (p<0.05 and p=0.01 respectively).
Assessment of gene expression corresponding to proteins assessed using 
immunohistochemistry.
Of the proteins assessed using immunohistochemistry, only the gene for MBP was 
differentially expressed. In salt-loaded WKY versus non-salt loaded WKY, MBP was 
down regulated in the frontal section (-2.6-fold), immunohistochemistry showed 
protein levels of MBP to be significantly more in the cortical grey matter of the frontal 
section (1.99 vs 0.47%, p<0.01) whilst being significantly decreased in the white 
matter of both frontal (0.35 vs 1.4%, p<0.05) and mid-coronal sections (0.521 vs 
1.66%, p<0.01) of salt-loaded WKY versus non-salt loaded WKY (figure 6). 
In salt-loaded versus non-salt loaded SHRSP, MBP was up-regulated by +2.2-fold in 
the frontal section. Immunohistochemistry showed protein levels of MBP to be 
significantly increased in the frontal deep grey matter (1.19 vs 0.47%, p<0.01), whilst 
being significantly decreased in the mid-coronal white matter (0.06 vs 1.1%, p<0.05) 
thereby agreeing with salt-loaded WKY versus non-salt loaded WKY. There was no 
difference in MBP gene expression between salt-loaded WKY and salt-loaded SHRSP, 
however immunohistochemistry showed a significant decrease in MBP protein levels 
in the cortical grey matter of the frontal section (0.43 vs 1.99%, p<0.01) and the white 
matter of the mid-coronal section (0.06 vs 0.52%, p<0.05)(figure 6).
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DISCUSSION 
This study has highlighted changes with dietary salt-loading in gene and protein 
expression in networks affecting inflammatory pathways, vascular structure and 
myelin integrity in the brains of SHRSP, a sporadic model of SVD, and in its parent 
strain, the WKY rat (for a diagrammatic summary see figure 7). In salt-loaded WKY 
rats, these changes occurred independently of an increase in blood pressure. Taken 
together, these results suggest that additional dietary salt may produce tissue changes 
indicative of SVD-related damage that are at least in part independent of the level of 
blood pressure.
Whilst this study consisted of a relatively small sample size and a short duration of 
salt-loading (3 weeks), rats were randomly selected from the Glasgow colony for 
both the control and salt-loaded groups, careful blinding was undertaken and only
established validated techniques were used. Both protein and gene expression 
changes were assessed in the same animals, reducing between-animal noise and 
confirming previously reported genetic strain differences between WKY and 
SHRSP(10) including the upregulation of GUCY1a3 and down-regulation of 
MRPL18 and ALB. These between-strain differences - which represent changes 
associated with the nitric oxide, inflammatory and connective tissue pathways - were 
larger in magnitude than the effects of salt-loading indicating the effect of rat strain 
is dominant. However, the fact that differences were found with a short period of 
salt-loading in both strains cannot be ignored and whilst the majority of changes in 
gene expression were small in terms of fold change (meaning confirmation with PCR 
was difficult), in combination and in the long term they could be extremely 
detrimental. Indeed a recent study in mice has implicated excess salt in endothelial 
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dysfunction caused via inhibition of eNOS phosphorylation and reduced production 
of NO(6). In turn this resulted in cognitive deficits in the salt-fed mice when tested 
for spatial memory, novel object recognition and nesting behaviour. 
Pathways pertaining to oxidative stress and inflammation showed changes in gene 
expression due to salt-loading in both strains. Acute phase response signalling 
contained the most differentially expressed genes in all salt versus no salt comparisons, 
whilst pathways pertaining to oxidative stress and leukocyte extravasation were also 
significantly affected. Increased expression of ALB and decreased expression of 
LOC100129193 have previously been implicated in hyperhomocysteinemia(14),
however in both salt-loaded WKY and SHRSP this study saw an increase in 
LOC100129193 and a decrease in ALB. This disagreement suggests salt-loading may 
influence inflammatory pathways over different time periods or durations of exposure 
or that they may not act via homocysteine.  
TTR expression was highly influenced by dietary salt in SHRSP being up-regulated by 
over +50-fold in frontal brain sections (though down-regulated in mid-coronal 
sections), and being amongst the 10 most upregulated genes in the salt-loaded WKY 
v WKY. TTR was also 7-fold more up-regulated in the salt-loaded SHRSP v salt-
loaded WKY whereas it was only upregulated by 2-fold in the mid-coronal section of 
salt-loaded WKY v WKY and therefore did not make the top 10. TTR has been 
previously shown to have associations with senile systemic amyloidosis and plasma 
cell dyscrasias providing some evidence of a direct linkage  to the immune response 
and potentially to the dementia-related effects of SVDs(15).
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In salt-loaded SHRSP at the protein level, we found increased reactive gliosis and 
activation of microglial cells compared to salt-loaded WKY. These results agree with 
previous data showing increased levels of oxidative stress and inflammation to be 
established responses to excessive salt intake in SHRSP(16, 17). Salt-loading also 
resulted in down-regulation of a gene network involved in maintaining vascular 
structure and tight junction signalling featured in the top 5 pathways affected in both 
salt-loaded WKY and SHRSP. Within the tight junction signalling pathway, we found 
CLDN11 gene expression was significantly down-regulated in salt-loaded versus non-
salt-loaded SHRSP and conversely up-regulated in salt-loaded SHRSP compared to 
salt-loaded WKY. As the SHRSP already has reduced Claudin-5 protein expression 
independent of salt-loading(9) the difference in Claudin-11 could indicate increased 
leakiness of blood vessels particularly when coupled with changes in gene expression 
of Albumin. The difference in immunoreactivity of Claudin-5 between the strains at 
21 weeks of age was absent in salt-loaded animals because the salt-loaded WKY rats 
also had less Claudin-5. These results suggest that WKY also develop vascular damage 
in the presence of salt-loading. The changes in APP and MBP as well as VWF and 
VGF in salt-loaded WKY versus WKY could indicate further impairments to vascular 
structure, and underline the importance of avoiding salt-loading in studies of blood
brain barrier integrity.
Furthermore, salt-loading caused differential expression of genes associated with 
myelin integrity in both strains. In WKY rats, several genes in a network centred round 
APP and MBP were up-regulated suggesting that expression of myelin-associated 
proteins would be increased. MBP immunoreactivity was also affected by salt-loading 
in WKY rats, although the changes were somewhat erratic with expression both 
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increasing and decreasing. As well as involvement in myelination, MBP is directly 
involved in T-lymphocyte mediated inflammation which can also lead to increased 
permeability of the BBB(13). Indeed many studies have suggested an inflammatory 
mechanism in salt-loaded rats which in turn compromises the blood brain barrier(11, 
12). Genes centred round APP and MBP were down-regulated in salt-loaded versus 
non-salt loaded SHRSP and we also saw decreased MBP immunoreactivity with salt-
loading in SHRSP. This suggests a different response to salt in WKY versus SHRSP 
or could represent a different stage in a disease process and requires further 
investigation.
The SHRSP is considered a relevant model of sporadic SVD in its naïve state(7).
SHRSP develop high levels of hypertension with systolic pressures of over 
170mmHg in contrast to normal levels of systolic pressure in WKY of 130-
140mmHg(18). Salt-loaded SHRSP regularly display systolic blood pressures of over 
200mmHg and accelerated end stage pathology (19) meaning they rarely live beyond 
28 weeks of age. In the SHRSP, solute carriers such as SLC24a2 (a 
sodium/potassium/calcium exchanger) were frequently within the top 10 up or down-
regulated genes. The fact that these genes were affected in SHRSP and not WKY 
provides further evidence of the salt sensitivity of the SHRSP(20).
A recent translational study tested associations between genes differentially 
expressed in the brains of young SHRSP and human WMH(21) and, despite these 
genes having small fold changes individually, collectively they showed positive 
associations with human WMH, consistent with the hypothesis that WMH are 
multifactorial in nature and have a vascular component. The genes identified in this 
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study should therefore also be tested in clinical cohorts of small vessel disease 
patients to see if the effect of dietary salt translates. 
CONCLUSION
This study showed changes in both gene and protein expression in the cerebral tissue 
of salt-loaded WKY independent of changes in BP. In both strains, the cerebral 
changes are exacerbated by salt-loading, although the effect is more pronounced in the 
SHRSP. Studies to assess different durations of salt-loading in younger non-
hypertensive animals are required and salt intake should be further assessed in clinical 
studies of SVD. Studies using the SHRSP as a model of cerebral SVD should refrain 
from salt-loading their animals to prevent complicating an already intricate set of 
pathological changes.
Clinical Significance
x The effect of salt on cerebral small vessel disease (SVD) is poorly understood 
and dietary salt is difficult to measure & control in the clinic. Therefore the
Spontaneously Hypertensive Stroke Prone Rat – a relevant experimental 
model was used to assess the effects of dietary salt on cerebral gene & protein 
expression. 
x Dietary salt-loading caused changes in gene and protein expression in 
networks affecting inflammatory pathways, vascular structure and myelin 
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integrity in the brains of SHRSP, and in its parent strain, the WKY rat. In the 
latter changes occurred independently of blood pressure elevation.
x The genes identified in this study should be tested in clinical cohorts of small 
vessel disease patients to see if the effect of dietary salt translates from bench 
to bedside.
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Figure Legends
Figure 1.  Four way Venn diagram from rank products analysis representing genes that were 
significantly differentially expressed in comparisons of salt (S) vs no salt animals, within A: 
SHRSP (SP) frontal (F) brain sections; B: WKY frontal brain sections; C: SHRSP mid-
coronal (M) brain sections; D: WKY mid-coronal brain sections.  The total number of 
significantly differentially expressed genes is given in brackets outside the relevant Venn 
rectangle (112 for A, 59 for B, 9 for C, 78 for D).  Within the rectangles every possible 
combination of these sets of significant genes is given.  For example: (A___) shows there 
were 83 genes that were only significant for the A comparison; (AB__) shows there were 7 
genes that were significant for both the A and B comparisons but not for C and D; (ABC_) 
shows there were 0 genes that were significant for the A, B and C comparisons but not for D; 
(ABCD) shows there was 1 gene significant for all four of the comparisons.
 
Figure 2. An IPA software network representing interactions between differentially 
expressed genes within frontal brain sections. Green = down-regulated genes and red = up-
regulated genes. Statistics quoted are, from top to bottom – p value, fold change and signal 
intensity. Solid lines indicate direct interactions. Dotted lines indicate indirect interactions. 
A) salt-loaded versus non-salt loaded WKY, B) the same network overlaid with salt-loaded 
versus non-salt loaded SHRSP data therefore genes highlighted in red indicate genes up 
regulated in salt-loaded SHRSP compared to SHRSP. For full numerical data corresponding 
to this figure see supplementary material. 
Figure 3. An IPA software network representing interactions between differentially 
expressed genes within the frontal sections of salt-loaded SHRSP versus non-salt loaded 
SHRSP. All genes highlighted in green are down regulated in salt-loaded SHRSP. Genes 
highlighted red are up regulated in salt-loaded SHRSP. Statistics quoted are from top to 
bottom – p value, fold change and signal intensity. Solid lines indicate direct interactions. 
Dotted lines indicate indirect interactions. For full numerical data corresponding to this 
figure see supplementary material. 
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Figure 4. The top 5 biological pathways in IPA containing an over representation of 
significantly differentially expressed genes in the frontal sections of A) Salt-loaded WKY 
versus non-salt loaded WKY, B) Salt-loaded SHRSP versus salt-loaded WKY and C) Salt-
loaded SHRSP versus non-salt-loaded SHRSP. The blue bar represents how significant the 
uploaded data set is to the pathway (log p value) and the orange line represents the number 
of genes differentially expressed as a proportion of the total genes within that pathway.   
Figure 5. Immunoreactivity of GFAP in frontal and mid-coronal sections. Each bar 
represents N=5. Error bars represent standard error of the mean. Staining panel A) Non-salt 
loaded WKY B) Salt-loaded WKY C) Non-salt loaded SHRSP D) Salt-loaded SHRSP. All 
images taken at x10 objective in the deep grey matter of a frontal section. 
Figure 6. Immunoreactivity of MBP in frontal and mid-coronal sections. Each bar represents 
N=5. Error bars represent standard error of the mean. Staining panel A) Non-salt loaded 
WKY B) Salt-loaded WKY C) Non-salt loaded SHRSP D) Salt-loaded SHRSP. All images 
taken at x4 objective in the cortical grey matter of a frontal section. 
Figure 7. A diagrammatical summary of both genetic and protein changes affecting the 
neurovascular unit observed in the cerebral tissue of salt-loaded WKY and SHRSP rats.
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Table 1. Results are for each brain section. N=4 for all groups. All genes listed are significantly 
expressed when a FDR of q<0.05 is applied. LOC100129193 = major urinary protein pseudogene.
AMBP = alpha-1-microglobulin/bikunin precursor. APOH = Apolipoprotein H. ALDOB = aldolase B, 
fructose-bisphosphate. AHSG = alpha-2-HS-glycoprotein. GC = group specific component. GPM6A = 
glycoprotein m6a. TCEB1 = transcription elongation factor B (SIII), polypeptide 1. NTS = neurotensin. 
CPE = carboxypeptidase E. ACTB = Beta Actin. TSPAN7 = tetraspanin 7. MAP1B = microtubule-
associated protein 1B. PPP3CB = protein phosphatase 3, catalytic subunit, beta isoform. TPI1 = 
triosephosphate isomerase 1. NSF = N-ethylmaleimide-sensitive factor. PKM2 = pyruvate kinase, 
muscle. SETD3 = SET domain containing 3. TMEM27 = transmembrane protein 27. SLCO1A5 = 
solute carrier organic anion transporter family, member 1a5. MCTP1 = multiple C2 domains, 
transmembrane 1. TAC1 = tachykinin 1. GPR88 = G Protein coupled receptor 88. TTR = Transthyretin. 
LRRC7 = leucine rich repeat containing 7.  SLC17A6 = solute carrier family 17 member 6. SLC24A2 = 
solute carrier family 24 member 2. OPCML = opioid binding protein/cell adhesion molecule-like. VGF 
= Vascular growth factor. PRKCG = protein kinase C, gamma. SOSTDC1 = sclerostin domain 
containing 1. OTX2 = orthodenticle homeobox 2. F5 = coagulation factor V. GDI1 = GDP dissociation 
inhibitor 1. SNURF = SNRPN upstream reading frame. VOPP1 = vesicular, over expressed in cancer, 
prosurvival protein 1.  SEC61G = SEC61, gamma subunit. ROCK2 = Rho-associated coiled-coil 
containing protein kinase 2. CYR61 = cysteine-rich, angiogenic inducer, 61. HBXIP = hepatitis B virus 
x interacting protein. MYEF2 = myelin expression factor 2. GSK3B = glycogen synthase kinase 3 beta. 
IL11 = Interleukin 11. HBB = hemoglobin, beta. SEPT7 = septin 7. CABP7 = calcium binding protein 
7. ANXA1 = annexin A1. ADORA2A = adenosine A2a receptor. AQP1 = aquaporin 1. SCN4B = 
sodium channel, voltage-gated, type IV, beta. SLC32A1 – solute carrier family 32 member 1. RASD2 = 
RASD family, member 2. DLX5 = distal-less homeobox 5. PMCH = pro-melanin-concentrating 
hormone. SIPA1L2 = signal-induced proliferation-associated 1 like 2. RGD = Rat genome database. 
RSP9 = Ribosomal protein 9. GUCY1a3 = Guanylate cyclase alpha subunit 3. FAM151B = family with 
sequence similarity 151, member B. ZNF597 = Zinc finger protein 597. OXT = Oxytocin. MRPL18 = 
Mitochondrial ribosomal protein L18.PXPM4 = peroxisomal membrane protein 4. GPR18 = G protein 
coupled receptor 18. CSNK2A1 = casein kinase 2, alpha 1 polypeptide. AVP = Arginine vasopressin. 
HLA-C = major histocompatibility complex, class I.
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Table 1. The top 10 up and down regulated genes within and between strain and salt comparisons.
Results are for each brain section. N=4 for all groups. All genes listed are significantly expressed when a FDR of q<0.05 is applied
LOC100129193 = major urinary protein pseudogene. AMBP = alpha-1-microglobulin/bikunin precursor. APOH = Apolipoprotein H. ALDOB = aldolase B, fructose-
bisphosphate. AHSG = alpha-2-HS-glycoprotein. GC = group specific component. GPM6A = glycoprotein m6a. TCEB1 = transcription elongation factor B (SIII), 
polypeptide 1. NTS = neurotensin. CPE = carboxypeptidase E. ACTB = Beta Actin. TSPAN7 = tetraspanin 7. MAP1B = microtubule-associated protein 1B. PPP3CB = 
protein phosphatase 3, catalytic subunit, beta isoform. TPI1 = triosephosphate isomerase 1. NSF = N-ethylmaleimide-sensitive factor. PKM2 = pyruvate kinase, muscle. 
SETD3 = SET domain containing 3. TMEM27 = transmembrane protein 27. SLCO1A5 = solute carrier organic anion transporter family, member 1a5. MCTP1 = multiple C2 
domains, transmembrane 1. TAC1 = tachykinin 1. GPR88 = G Protein coupled receptor 88. TTR = Transthyretin. LRRC7 = leucine rich repeat containing 7.  SLC17A6 = 
solute carrier family 17 member 6. SLC24A2 = solute carrier family 24 member 2. OPCML = opioid binding protein/cell adhesion molecule-like. VGF = Vascular growth 
factor. PRKCG = protein kinase C, gamma. SOSTDC1 = sclerostin domain containing 1. OTX2 = orthodenticle homeobox 2. F5 = coagulation factor V. GDI1 = GDP 
dissociation inhibitor 1. SNURF = SNRPN upstream reading frame. VOPP1 = vesicular, over expressed in cancer, prosurvival protein 1.  SEC61G = SEC61, gamma subunit. 
ROCK2 = Rho-associated coiled-coil containing protein kinase 2. CYR61 = cysteine-rich, angiogenic inducer, 61. HBXIP = hepatitis B virus x interacting protein. MYEF2 = 
myelin expression factor 2. GSK3B = glycogen synthase kinase 3 beta. IL11 = Interleukin 11. HBB = hemoglobin, beta. SEPT7 = septin 7. CABP7 = calcium binding protein 
7. ANXA1 = annexin A1. ADORA2A = adenosine A2a receptor. AQP1 = aquaporin 1. SCN4B = sodium channel, voltage-gated, type IV, beta. SLC32A1 – solute carrier
family 32 member 1. RASD2 = RASD family, member 2. DLX5 = distal-less homeobox 5. PMCH = pro-melanin-concentrating hormone. SIPA1L2 = signal-induced 
proliferation-associated 1 like 2. RGD = Rat genome database. RSP9 = Ribosomal protein 9. GUCY1a3 = Guanylate cyclase alpha subunit 3. FAM151B = family with 
sequence similarity 151, member B. ZNF597 = Zinc finger protein 597. OXT = Oxytocin. MRPL18 = Mitochondrial ribosomal protein L18.PXPM4 = peroxisomal 
membrane protein 4. GPR18 = G protein coupled receptor 18. CSNK2A1 = casein kinase 2, alpha 1 polypeptide. AVP = Arginine vasopressin. HLA-C = major 
histocompatibility complex, class C. VPS13C = vacuolar protein sorting 13 homologue.
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METHODS 
Animals 
All animals were kept and experiments conducted according to UK regulations for live 
animal research in licensed laboratories (licence No. 60/3618) and conducted according to the 
ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines 
(http://www.nc3rs.org/ARRIVE). Results are reported according to the Minimum 
Information About a Microarray Experiment (MIAME) 2.0 criteria 
(http://www.mged.org/Workgroups/MIAME/miame_2.0.html). All animals were obtained 
from the Glasgow colony and kept in identical conditions [8].  
Study animals consisted of male rats aged 21 weeks reared on either a normal diet (n = 5 per 
strain) or a normal diet until age 18 weeks and then a ‘salt-loaded’ diet consisting of 1% 
NaCl added to drinking water from 18 to 21 weeks (n = 5 per strain).  
Tail cuff plethysmography was used to take weekly measurements of systolic blood pressure. 
Animals were sacrificed by overdose of isofluorane plus exsanguination. Brains were 
extracted and divided into left and right hemispheres – one fixed in formalin for 
immunohistochemistry, one snap frozen in liquid nitrogen for RNA extraction. 
 
Microarray 
For full methods see [9].For mRNA analysis, one hemisphere was snap frozen in RNA-later 
ice solution and 2 mm coronal slices from a frontal and a mid-coronal region were cut using a 
Zivic® rat slicer matrix. One region was selected at +1.8-mm bregma to capture a 
representative frontal section and a second region at −1.72-mm bregma to capture 
representative areas of the basal ganglia and internal capsule (mid-coronal section). These 
areas are typically affected in patients, and, from the published literature, typically are the 
most damaged areas in SHRSP [8]. 
RNA was extracted from homogenized coronal slices using a Qiagen RNAeasy lipid tissue 
minikit (Qiagen Ltd., Manchester, UK). Turbo DNase removed any remaining genomic DNA 
and RNA quality was assessed on a Nanodrop 1000 and Agilent® bioanalyser 2100 (Agilent, 
Santa Clara, CA, USA). RNA was transcribed to cRNA using an Ambion® Illumina® Total 
Prep RNA amplification kit (Applied Biosystems, Foster City, CA, USA). We obtained a 
final cRNA elute of ׽200μl and checked cRNA quality on an Agilent® bioanalyser. The 
resulting cRNA was loaded onto a RatRef12 microarray chip (Illumina, San Diego, CA, 
USA), containing 22 519 gene and probe sets and stained in a solution of E1 buffer plus 
1:1000 dilution of streptavidin-Cy3. Chips were scanned on an Illumina® Bead Reader 
(Illumina, San Diego, CA, USA) for fluorescence intensity. Samples with a signal intensity of 
>600 passed the bead array reader's quality control. We randomized samples throughout the 
entire microarray protocol and all samples were hybridized to the chips and scanned at the 
same time. 
qRT-PCR: To quantitatively confirm differential expression from the microarray the same 
DNase-treated RNA was used as a template for synthesis of cDNA, qRT-PCR reactions using 
Applied Biosystems Taqman® Gene Expression Assay (Applied Biosystems, Foster City, 
CA, USA). The reaction mix included Taqman® universal master mix (Applied Biosystems, 
Foster City, CA, USA) plus GAPDH (VIC® labelled)] and Taqman® probes corresponding 
to our gene of interest (FAM® labelled).  
Data Analysis: Microarray data were analysed using Rank Products (RP) analysis complete 
with Bejamini-Hochberg false discovery rate (FDR) adjustment for multiple testing. 
FDR <0.05 was considered significant. A minimum individual fold change for significance 
was not set due to an interest in pathway interactions. Venn diagrams were used to visualize 
the results by age and brain section, then Ingenuity Pathway Analysis® (IPA) (Ingenuity 
Systems, http://www.ingenuity.com) analysed data using both a prespecified candidate gene 
approach (looking for changes in genes and pathways thought to be relevant from previous 
work by ourselves and others) and a genome-wide approach (to generate new hypotheses). 
Significance of pathways was assessed using one-sided Fisher's exact tests. 
qRT-PCR data (cycle threshold (CT) values) was analysed in Microsoft® Excel by 
comparing mean delta cycle threshold (dCT) values vs. the housekeeper gene using a 
Student's t-test.  
Immunohistochemistry 
Tissue preparation: Formalin-fixed tissue was sectioned into 3-mm-thick coronal slices, 
processed and embedded in paraffin blocks, which were then cut into 7-μm sections. Similar 
frontal and mid coronal sections were chosen for analysis. “Standard coordinates from a 
stereotactic atlas were used to identify prominent structures (e.g. the internal capsule). The 
frontal region encompassed a region approximately +1.8-mm bregma (containing the anterior 
commissure and anterior lateral ventricle) and the mid coronal captured a region at −1.72-mm 
bregma (including areas of the basal ganglia and internal capsule)”.  
  
Antibody staining: Antibodies assessed various components of the neurovascular unit, 
claudin-5, collagen IV, smooth muscle actin (SMA), collagen I, glial fibrillary acidic protein 
(GFAP), matrix metalloproteinase 9 (MMP9), ionized calcium-binding adaptor molecule 1 
(Iba-1) and Myelin Basic Protein (MBP). We  previously assessed this panel of antibodies in 
5 and 16 week old WKY and SHRSP [8]. All immunohistochemical studies used the ABC 
immunoperoxidase method (Vector Laboratories, Peterborough, UK). Antigen heat retrieval 
using a pressure cooker (with slides immersed in citric acid buffer) was performed before 
slides were blocked in hydrogen peroxide followed by either rabbit or swine serum. 3.3′-
diaminobenzidine tetrahydrochloride with a haematoxylin counterstain revealed 
immunoreactivity. Tris-buffered saline replaced the primary antibody in negative controls. 
Data analysis: Percentage staining within a defined area of interest was generated using 
ImagePro™ software (version 6.2; Media Cybernetics, Bethesda, MD, USA), blinded to 
species and salt, in cortical, deep grey and white matter. A standard sampling protocol was 
developed by identifying cross sections using landmarks such as the rhinal fissure and 
piriform cortex (for full protocol see [8]). Each cross section was divided into cortical grey 
matter, white matter and deep grey matter using the freehand tool on ImagePro™. Intra-
observer reliability was assessed using a randomly selected slide counted on five separate 
occasions and revealed less than 10% of the variance within the counts was due to the effect 
of day. Colour-matched pixel counts applied to the entire hemisphere and subsequently 
converted into percentage areas of staining as a measure of immunoreactivity using 
ImagePro™, once each region of interest (e.g. cortical grey) had been defined by hand. 
We performed statistical analysis in Minitab using a general linear model (two-way ANOVA) 
followed by Tukeys test for pairwise comparisons. The effect of both salt diet and strain were 
analysed. Frontal cortex and mid-coronal sections were analysed separately due to significant 
differences in the distribution of grey and white matter, and the influence of brain territory on 
expression was also included. P values of p<0.05 were considered statistically significant. All 
data are shown as mean ± SEM. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data taken from frontal section tissue in 21 week old SHRSP versus WKY rats fed either a normal diet or salt-loaded with 1% NaCl from the age of 18 weeks. Numbers 
indicate percentage staining ± the standard error of the mean from n=5 animals. NS = No significant difference. 
 
SECTION FRONTAL SECTION 
SALT No Salt Salt 
REGION Cortex White Matter Deep Grey Cortex White Matter Deep Grey 
Claudin5 
WKY 0.280±0.123 0.268±0.127 0.231±0.162 0.160±0.063 0.112±0.057 0.085±0.049 
SHRSP 0.132±0.027 0.073±0.045 0.048±0.033 0.104±0.029 0.126±0.048 0.117±0.087 
P for salt 
WKY:WKY+NaCl 
No significant differences 
WKY+NaCl:SHRSP+NaCl 
No significant differences 
SHRSP:SHRSP+NaCl  
No significant differences 
Collagen I 
WKY 0.172±0.047 0.134±0.079 0.120±0.072 0.094±0.050 0.080±0.039 0.077±0.051 
SHRSP 0.138±0.100 0.066±0.032 0.030±0.014 0.097±0.064 0.099±0.067 0.030±0.014 
P for salt 
WKY:WKY+NaCl  
No significant differences   
WKY+NaCl:SHRSP+NaCl  
No significant differences 
SHRSP:SHRSP+NaCl  
No significant differences 
Collagen 
IV 
WKY 0.183±0.120 0.234±0.162 0.062±0.017 0.203±0.142 0.106±0.062 0.089±0.025 
SHRSP 0.361±0.074 0.120±0.032 0.100±0.044 0.113±0.053 0.041±0.028 0.098±0.049 
P for salt 
WKY:WKY+NaCl  
No significant differences   
WKY+NaCl:SHRSP+NaCl  
No significant differences   
SHRSP:SHRSP+NaCl  
Cortex p=0.02    White = NS   Deep Grey = NS 
SMA 
WKY 0.189±0.075 0.100±0.049 0.139±0.043 0.298±0.161 0.087±0.025 0.146±0.056 
SHRSP 0.356±0.121 0.260±0.136 0.199±0.087 0.231±0.027 0.171±0.094 0.139±0.067 
P for salt 
WKY:WKY+NaCl  
No significant differences 
WKY+NaCl:SHRSP+NaCl  
No significant differences 
SHRSP:SHRSP+NaCl  
No significant differences 
Table S1. Results of ANOVA analysis on the effect of salt on the percentage staining of 4 antibodies assessing vascular structure. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 Data taken from mid coronal tissue in 21 week old SHRSP versus WKY rats fed either a normal diet or salt-loaded with 1% NaCl from the age of 18 weeks. Numbers indicate 
percentage staining ± the standard error of the mean from n=5 animals. NS = No significant difference. 
 
SECTION MID CORONAL SECTION 
SALT No Salt Salt 
REGION Cortex White Matter Deep Grey Cortex White Matter Deep Grey 
Claudin5 
WKY 0.200±0.025 0.261±0.140 0.414±0.125 0.233±0.122 0.144±0.084 0.439±0.222 
SHRSP 0.080±0.070 0.129±0.058 0.113±0.084 0.177±0.103 0.233±0.054 0.223±0.085 
P for salt 
WKY:WKY+NaCl 
No significant differences 
WKY+NaCl:SHRSP+NaCl 
No significant differences 
SHRSP:SHRSP+NaCl  
No significant differences 
Collagen I 
WKY 0.088±0.064 0.060±0.012 0.732±0.381 0.242±0.150 0.131±0.080 0.475±0.202 
SHRSP 0.308±0.135 0.147±0.081 0.356±0.237 0.154±0.050 0.171±0.138 0.349±0.135 
P for salt 
WKY:WKY+NaCl  
No significant differences   
WKY+NaCl:SHRSP+NaCl  
No significant differences 
SHRSP:SHRSP+NaCl  
No significant differences 
Collagen 
IV 
WKY 0.239±0.089 0.265±0.121 0.151±0.018 0.311±0.100 0.116±0.068 0.230±0.153 
SHRSP 0.183±0.112 0.054±0.033 0.146±0.044 0.413±0.198 0.229±0.143 0.239±0.085 
P for salt 
WKY:WKY+NaCl  
No significant differences   
WKY+NaCl:SHRSP+NaCl  
No significant differences   
SHRSP:SHRSP+NaCl  
No significant differences   
SMA 
WKY 0.292±0.044 0.385±0.183 0.291±0.087 0.262±0.076 0.219±0.092 0.649±0.187 
SHRSP 0.530±0.237 0.517±0.231 0.704±0.352 0.426±0.200 0.403±0.118 0.398±0.252 
P for salt 
WKY:WKY+NaCl 
Cortex = NS    White = NS    Deep Grey p<0.05 
WKY+NaCl:SHRSP+NaCl  
No significant differences 
SHRSP:SHRSP+NaCl  
                  No significant differences 
Table S2. Results of ANOVA analysis on the effect of salt on the percentage staining of 4 antibodies assessing vascular structure. 
  
Data taken from frontal tissue in 21 week old SHRSP versus WKY rats fed either a normal diet or salt-loaded with 1% NaCl from the age of 18 weeks. Numbers indicate 
percentage staining ± the standard error of the mean from n=5 animals. NS = No significant difference. 
 
SECTION FRONTAL SECTION 
SALT No Salt Salt 
REGION Cortex White Matter Deep Grey Cortex White Matter Deep Grey 
MMP9 
WKY 0.349±0.211 0.154±0.101 0.096±0.065 0.132±0.098 0.112±0.073 0.087±0.057 
SHRSP 0.148±0.077 0.143±0.081 0.030±0.023 0.264±0.106 0.248±0.174 0.158±0.132 
P for salt 
WKY:WKY+NaCl 
No significant differences 
WKY+NaCl:SHRSP+NaCl  
No significant differences 
SHRSP:SHRSP+NaCl 
No significant differences 
GFAP 
WKY 0.914±0.199 1.387±0.254 1.490±0.567 0.493±0.136 1.991±0.230 0.835±0.161 
SHRSP 0.715±0.169 2.419±0.758 1.034±0.304 1.046±0.299 1.840±0.314 1.190±0.139 
P for salt 
WKY:WKY+NaCl  
Cortex p<0.05       White = NS      Deep Grey = NS      
WKY+NaCl:SHRSP+NaCl  
Cortex p<0.01      White = NS      Deep Grey = NS 
SHRSP:SHRSP+NaCl  
No significant differences 
IBA-1 
WKY 0.063+0.013 0.109+0.042 0.048+0.013 0.031+0.011 0.054+0.016 0.027+0.010 
SHRSP 0.071+0.035 0.084+0.048 0.052+0.028 0.014+0.002 0.030+0.013 0.051+0.026 
P for salt 
WKY:WKY+NaCl 
No significant differences    
WKY+NaCl:SHRSP+NaCl  
No significant differences 
SHRSP:SHRSP+NaCl  
Cortex p<0.01      White = NS     Deep Grey = NS 
MBP 
WKY 0.477±0.191 1.402±0.611 1.690±0.697 1.990±0.794 0.346±0.117 1.165±0.092 
SHRSP 0.462±0.204 0.632±0.224 0.472±0.286 0.427±0.237 0.561±0.294 1.189±0.290 
P for salt 
WKY:WKY+NaCl  
Cortex p=0.01      White p<0.05     Deep Grey = NS  
WKY+NaCl:SHRSP+NaCl  
Cortex p<0.01      White = NS     Deep Grey = NS 
SHRSP:SHRSP+NaCl  
Cortex = NS    White = NS    Deep Grey =  p<0.01 
Table S3. Results of ANOVA analysis on the effect of salt on the percentage staining of 4 antibodies assessing the presence / absence of vascular disease. 
  
 
Data taken from mid coronal tissue in 21 week old SHRSP versus WKY rats fed either a normal diet or salt-loaded with 1% NaCl from the age of 18 weeks. Numbers indicate 
percentage staining ± the standard error of the mean from n=5 animals. NS = No significant difference. 
 
SECTION MID CORONAL SECTION 
SALT No Salt Salt 
REGION Cortex White Matter Deep Grey Cortex White Matter Deep Grey 
MMP9 
WKY 0.141±0.058 0.217±0.013 0.521±0.171 0.162±0.115 0.367±0.225 0.717±0.346 
SHRSP 0.452±0.232 0.207±0.102 0.380±0.196 0.350±0.225 0.119±0.056 0.375±0.182 
P for salt 
WKY:WKY+NaCl  
No significant differences 
                  WKY+NaCl:SHRSP+NaCl  
No significant differences 
SHRSP:SHRSP+NaCl  
No significant differences 
GFAP 
WKY 0.683±0.302 2.388±0.529 1.898±0.496 0.615±0.174 2.439±0.382 2.551±0.382 
SHRSP 0.702±0.172 2.093±0.500 2.246±0.515 0.504±0.162 3.965±0.766 2.552±0.702 
P for salt 
WKY:WKY+NaCl  
 No significant differences   
WKY+NaCl:SHRSP+NaCl  
Cortex = NS         White p<0.05       Deep Grey = NS 
SHRSP:SHRSP+NaCl  
Cortex = NS       White p<0.01     Deep Grey = NS 
IBA-1 
WKY 0.032+0.020 0.022+0.011 0.013+0.006 0.055+0.020 0.034+0.021 0.019+0.009 
SHRSP 0.045+0.015 0.034+0.019 0.036+0.020 0.112+0.033 0.109+0.099 0.063+0.026 
P for salt 
WKY:WKY+NaCl  
No significant differences    
WKY+NaCl:SHRSP+NaCl  
Cortex p<0.05      White = NS     Deep Grey p=0.01 
SHRSP:SHRSP+NaCl  
Cortex p=0.01      White = NS     Deep Grey = NS 
MBP 
WKY 4.622±2.152 1.659±0.634 0.582±0.228 3.834±1.410 0.521±0.150 0.292±0.107 
SHRSP 1.570±0.786 1.098±0.761 0.383±0.233 1.944±0.886 0.063±0.046 0.130±0.105 
P for salt 
WKY:WKY+NaCl  
Cortex = NS   White = p<0.01  Deep Grey = NS 
WKY+NaCl:SHRSP+NaCl  
Cortex = NS      White =  p<0.05   Deep Grey = NS 
SHRSP:SHRSP+NaCl  
Cortex = NS      White = p<0.05     Deep Grey = NS 
Table S4. Results of ANOVA analysis on the effect of salt on the percentage staining of 4 antibodies assessing the presence / absence of vascular disease. 
  
 
 
 
 
 
 
 
SHRSP S vs NS Frontal      
Symbol Entrez Gene Name Expr p-value Expr Fold Change Location Family 
ACTB actin beta 0.000363636 3.664505185 Cytoplasm other 
AHSG alpha 2-HS glycoprotein 0.886386098 1.564397312 Extracellular Space other 
ALB albumin 0.252661871 2.18686048 Extracellular Space transporter 
AMBP 
alpha-1-
microglobulin/bikunin 
precursor 0.420691928 1.687026301 Extracellular Space transporter 
APP APP 0.229076305 1.867222156 Plasma Membrane other 
CPE CPE 0.000833333 3.790831982 Plasma Membrane peptidase 
MAP1B 
microtubule associated 
protein 1B 0.00969697 3.039544736 Cytoplasm other 
MBP myelin basic protein 0.027260442 2.159306134 Extracellular Space other 
NSF 
N-ethylmaleimide 
sensitive factor, vesicle 
fusing ATPase 0.022399404 2.308452769 Cytoplasm transporter 
NTS neurotensin 0.552521408 1.529705972 Extracellular Space other 
TTR transthyretin 0 53.37301373 Extracellular Space transporter 
WKY S v NS Frontal      
Symbol Entrez Gene Name Expr p-value Expr Fold Change Location Family 
ACTB actin beta 0.002937063 -2.254365334 Cytoplasm other 
AHSG alpha 2-HS glycoprotein 0.028353808 2.161816113 Extracellular Space other 
ALB albumin 0.01 2.038292073 Extracellular Space transporter 
AMBP 
alpha-1-
microglobulin/bikunin 
precursor 0.011185771 2.61159513 Extracellular Space transporter 
APP APP 0.041423671 -1.825170257 Plasma Membrane other 
CPE CPE 0.001363636 -2.381731904 Plasma Membrane peptidase 
MAP1B 
microtubule associated 
protein 1B 0.009760766 -2.191795586 Cytoplasm other 
MBP myelin basic protein 0.000649351 -2.636272104 Extracellular Space other 
NSF 
N-ethylmaleimide 
sensitive factor, vesicle 
fusing ATPase 0.039690522 -1.945245839 Cytoplasm transporter 
NTS neurotensin 0.041423671 1.823815196 Extracellular Space other 
TTR transthyretin 0.036727273 -1.009580577 Extracellular Space transporter 
SHRSP Salt vs No Salt      
Symbol Entrez Gene Name Expr p-value Expr Fold Change Location Family 
ACTB actin beta 0.000363636 3.664505185 Cytoplasm other 
CAPNS1 calpain small subunit 1 0.017414141 2.132061626 Cytoplasm peptidase 
CTNNB1 catenin beta 1 0.004545455 2.700607847 Nucleus transcription regulator 
DNAJB4 
DnaJ heat shock protein 
family (Hsp40) member 
B4 0.025200535 2.130853613 Nucleus other 
DSTN DSTN 0.012545455 2.516480202 Cytoplasm other 
HNRNPA2B1 
heterogeneous nuclear 
ribonucleoprotein A2/B1 0.040969125 1.883773987 Nucleus other 
KCNIP4 
potassium voltage-gated 
channel interacting protein 
4 0.029879518 2.234544061 Plasma Membrane ion channel 
MBP myelin basic protein 0.027260442 2.159306134 Extracellular Space other 
PLS3 plastin 3 0.02084048 2.149291695 Cytoplasm other 
ROCK2 
Rho associated coiled-coil 
containing protein kinase 
2 0.021338843 -1.914940256 Cytoplasm kinase 
RPL7 ribosomal protein L7 0.015159705 2.413802708 Cytoplasm transcription regulator 
YAF2 YAF2 0.016807611 2.083912782 Nucleus transcription regulator 
YY1 YY1 transcription factor 0.015159705 2.382734897 Nucleus transcription regulator 
 
